PL3061747T3 - Pochodne ketonów pirydynowych, sposób ich wytwarzania i ich zastosowanie farmaceutyczne - Google Patents

Pochodne ketonów pirydynowych, sposób ich wytwarzania i ich zastosowanie farmaceutyczne

Info

Publication number
PL3061747T3
PL3061747T3 PL14854930T PL14854930T PL3061747T3 PL 3061747 T3 PL3061747 T3 PL 3061747T3 PL 14854930 T PL14854930 T PL 14854930T PL 14854930 T PL14854930 T PL 14854930T PL 3061747 T3 PL3061747 T3 PL 3061747T3
Authority
PL
Poland
Prior art keywords
preparing same
ketone derivatives
pharmaceutical application
pyridic
pyridic ketone
Prior art date
Application number
PL14854930T
Other languages
English (en)
Inventor
Wangyang Tu
Haitang ZHANG
Guoji Xu
Jiangtao CHI
Original Assignee
Shanghai Hengrui Pharmaceutical Co. Ltd.
Jiangsu Hengrui Medicine Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd. filed Critical Shanghai Hengrui Pharmaceutical Co. Ltd.
Publication of PL3061747T3 publication Critical patent/PL3061747T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL14854930T 2013-10-25 2014-09-05 Pochodne ketonów pirydynowych, sposób ich wytwarzania i ich zastosowanie farmaceutyczne PL3061747T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310512377 2013-10-25
PCT/CN2014/085976 WO2015058589A1 (zh) 2013-10-25 2014-09-05 吡啶酮类衍生物、其制备方法及其在医药上的应用
EP14854930.6A EP3061747B1 (en) 2013-10-25 2014-09-05 Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof

Publications (1)

Publication Number Publication Date
PL3061747T3 true PL3061747T3 (pl) 2021-07-19

Family

ID=52992223

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14854930T PL3061747T3 (pl) 2013-10-25 2014-09-05 Pochodne ketonów pirydynowych, sposób ich wytwarzania i ich zastosowanie farmaceutyczne

Country Status (15)

Country Link
US (2) US9914703B2 (pl)
EP (1) EP3061747B1 (pl)
JP (1) JP6403172B2 (pl)
KR (1) KR102222569B1 (pl)
CN (1) CN104936945B (pl)
AU (1) AU2014339527B2 (pl)
BR (1) BR112016007396B1 (pl)
CA (1) CA2927635C (pl)
ES (1) ES2868450T3 (pl)
MX (1) MX377816B (pl)
PL (1) PL3061747T3 (pl)
PT (1) PT3061747T (pl)
RU (1) RU2667892C2 (pl)
TW (1) TWI662026B (pl)
WO (1) WO2015058589A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10118911B2 (en) * 2015-03-27 2018-11-06 Jiangsu Hengrui Medicine Co., Ltd. P-toluenesulfonate for MEK kinase inhibitor, and crystal form thereof and preparation method therefor
CN104892499B (zh) * 2015-06-26 2017-07-21 江西省科学院应用化学研究所 一种2‑吡啶酮类衍生物的合成方法
WO2018095403A1 (zh) 2016-11-25 2018-05-31 江苏恒瑞医药股份有限公司 一种吡啶酮类衍生物药物组合物及其制备方法
CN108884048B (zh) * 2016-12-01 2021-07-27 江苏恒瑞医药股份有限公司 一种吡啶酮类衍生物的制备方法及其中间体
CN108314645A (zh) * 2017-01-18 2018-07-24 上海映诺济生物科技有限公司 一类具有抗细胞增殖活性的化合物、制备方法和用途
SG11201912997TA (en) * 2017-06-23 2020-01-30 Cstone Pharmaceuticals Coumarin-like cyclic compound as mek inhibitor and use thereof
WO2020125747A1 (zh) * 2018-12-21 2020-06-25 基石药业(苏州)有限公司 一种mek抑制剂的晶型、无定形及其应用
WO2020156162A1 (zh) * 2019-01-29 2020-08-06 贝达药业股份有限公司 Mek抑制剂及其在医药上的应用
CN111514140B (zh) * 2019-02-01 2021-09-03 江苏恒瑞医药股份有限公司 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
TW202114994A (zh) * 2019-07-29 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種1,6-二氫吡啶-3-甲醯胺衍生物的製備方法
TW202114667A (zh) * 2019-09-11 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Mek抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤的藥物中的用途
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
AR121078A1 (es) * 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111848613B (zh) * 2020-08-11 2021-09-24 山东大学 一种二芳基嘧啶骈吡啶酮类衍生物及其制备方法与应用
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
PE20240879A1 (es) * 2021-08-17 2024-04-24 Kanaph Therapeutics Inc Inhibidor sos1 y uso del mismo
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN120441478A (zh) * 2024-02-07 2025-08-08 成都赜灵生物医药科技有限公司 一种六元内酰胺类化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003005969A2 (en) * 2001-07-12 2003-01-23 Bristol-Myers Squibb Pharma Company Tetrahydropurinones as corticotropin releasing factor
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
SI1761528T1 (sl) * 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
ES2405785T3 (es) * 2005-05-18 2013-06-03 Array Biopharma Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
CN101389609B (zh) * 2006-02-22 2012-01-11 霍夫曼-拉罗奇有限公司 基于乙内酰脲的激酶抑制剂
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
ES2426096T3 (es) * 2008-07-01 2013-10-21 Genentech, Inc. Derivados de isoindolona como inhibidores de la quinasa MEK y métodos de utilización
CN102134218A (zh) * 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂
US20120238599A1 (en) * 2011-03-17 2012-09-20 Chemizon, A Division Of Optomagic Co., Ltd. Heterocyclic compounds as mek inhibitors
WO2012162293A1 (en) * 2011-05-23 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
NZ629432A (en) * 2012-03-14 2017-01-27 Lupin Ltd Heterocyclyl compounds as mek inhibitors

Also Published As

Publication number Publication date
MX2016004742A (es) 2016-12-09
EP3061747B1 (en) 2021-04-07
US20160244410A1 (en) 2016-08-25
AU2014339527A1 (en) 2016-05-12
ES2868450T3 (es) 2021-10-21
BR112016007396B1 (pt) 2021-01-19
JP2016534027A (ja) 2016-11-04
CN104936945A (zh) 2015-09-23
TWI662026B (zh) 2019-06-11
KR20160074554A (ko) 2016-06-28
RU2016118753A (ru) 2017-11-29
EP3061747A1 (en) 2016-08-31
TW201518278A (zh) 2015-05-16
JP6403172B2 (ja) 2018-10-10
US10064848B2 (en) 2018-09-04
US9914703B2 (en) 2018-03-13
US20180016236A1 (en) 2018-01-18
BR112016007396A2 (pt) 2017-08-01
MX377816B (es) 2025-03-11
RU2667892C2 (ru) 2018-09-25
EP3061747A4 (en) 2017-05-10
KR102222569B1 (ko) 2021-03-05
CN104936945B (zh) 2017-11-03
CA2927635C (en) 2021-07-20
HK1212980A1 (zh) 2016-06-24
WO2015058589A1 (zh) 2015-04-30
AU2014339527B2 (en) 2018-07-19
RU2016118753A3 (pl) 2018-05-25
PT3061747T (pt) 2021-05-04
CA2927635A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
PL3061747T3 (pl) Pochodne ketonów pirydynowych, sposób ich wytwarzania i ich zastosowanie farmaceutyczne
PL3486242T3 (pl) Pochodna oksopikolinamidu, sposób jej wytwarzania i zastosowanie farmaceutyczne
HRP20161202T8 (hr) Novi derivati fosfata, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
SI2829539T1 (sl) Novi derivati pirola, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
EP3378859A4 (en) Benzofuran derivative, preparation method thereof and use thereof in medicine
EP2947084B8 (en) Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof
EP3040331A4 (en) Tetrahydrocyclopentapyrrole derivative and preparation method therefor
SMT201900573T1 (it) Derivati di pirazolopirimidone o pirrolotriazone, metodo di preparazione degli stessi, e applicazioni farma­ceutiche degli stessi
LT2998296T (lt) Cikloalkilo rūgšties darinys, jo gavimo būdas ir jo farmacinis taikymas
EP3181553A4 (en) Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
EP3231802A4 (en) Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof
SG11201604222YA (en) Capsule containing total flavonoids of desmodium styracifolium, method for preparing the same and use
EP3072893A4 (en) Ketone derivatives of imidazoles, pharmaceutical combinations and uses thereof
ZA201601343B (en) Vancomycin derivative, and preparation method and application thereof
PL3055679T3 (pl) Środek do wykrywania pęknięć, sposób jego wytwarzania i zastosowanie środka do wykrywania pęknięć
EP3072895A4 (en) Phillygenol sulphate and derivative thereof, and preparation method and application thereof
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
IL243227A0 (en) History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them
EP2955174A4 (en) HOMOSERIN LACTONE DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF
IL242543B (en) The history of tylosin and a method for its preparation
DK3091005T3 (da) 1,2-naphthoquinonderivat og fremgangsmåde til fremstilling deraf
EP2952519A4 (en) PROTOPANOXADIOL DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF
EP3087980A4 (en) Double-layer tablet and preparation method thereof
EP3056491A4 (en) Synthetic intermediate of maxacalcitol, preparation method therefor and use thereof
EP3052484A4 (en) Sulfonylindole derivatives and method for preparing the same